Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Published:2017-07 Issue:10090 Volume:390 Page:135-144
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Vermeire Séverine,Sandborn William J,Danese Silvio,Hébuterne Xavier,Salzberg Bruce A,Klopocka Maria,Tarabar Dino,Vanasek Tomas,Greguš Miloš,Hellstern Paul A,Kim Joo Sung,Sparrow Miles P,Gorelick Kenneth J,Hinz Michelle,Ahmad Alaa,Pradhan Vivek,Hassan-Zahraee Mina,Clare Robert,Cataldi Fabio,Reinisch Walter

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Ulcerative colitis;Ungaro;Lancet,2017

2. Ulcerative colitis;Ford;BMJ,2013

3. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review;Molodecky;Gastroenterology,2012

4. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target;Allocca;Expert Rev Clin Immunol,2014

5. Anti-adhesion molecule therapy for inflammatory bowel disease;Ghosh;Therap Adv Gastroenterol,2010

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Ontamalimab in Treating Inflammatory Bowel Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials;Current Pharmacology Reports;2024-09-05

2. Contribution of gut-derived T cells to extraintestinal autoimmune diseases;Trends in Immunology;2024-09

3. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins;The Korean Journal of Gastroenterology;2024-08-25

4. Mirikizumab Exposure–Response Relationships in Patients with Moderately‐to‐Severely Active Ulcerative Colitis in Randomized Phase II and III Studies;Clinical Pharmacology & Therapeutics;2024-05-26

5. Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis;Inflammation Research;2024-04-08